Company news

Share this article:
A US appeals court upheld a lower court ruling finding the Plavix patent valid, meaning patent protection will be maintained until November 2011. Sanofi-Aventis and Bristol-Myers Squibb are seeking damages from Canadian drug manufacturer Apotex Inc., which launched a generic version of Plavix in 2006. BMS has claimed that it lost as much as $1.75 billion in sales after Apotex's generic version of Plavix hit the market in 2006. Plavix is the world's second biggest drug and the biggest selling product for BMS and second-biggest for Sanofi, behind Lovenox. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.